Welcome to LookChem.com Sign In|Join Free
  • or
Pyrazinecarboxylic acid, 3-amino-6-phenyl, methyl ester is a complex organic compound with the chemical formula C12H12N2O2. It is a derivative of pyrazinecarboxylic acid, featuring an amino group at the 3-position and a phenyl group at the 6-position. The methyl ester functional group is attached to the carboxylic acid, making it a methyl ester of 3-amino-6-phenylpyrazine-2-carboxylic acid. Pyrazinecarboxylic acid, 3-amino-6-phenyl-, methyl ester is known for its potential applications in the synthesis of various pharmaceuticals and agrochemicals, as well as in the flavor and fragrance industry due to its unique properties. It is important to note that handling and usage of this chemical should be done with caution, following proper safety guidelines, as it may have certain toxicological properties.

1503-42-0

Post Buying Request

1503-42-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1503-42-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1503-42-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,0 and 3 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1503-42:
(6*1)+(5*5)+(4*0)+(3*3)+(2*4)+(1*2)=50
50 % 10 = 0
So 1503-42-0 is a valid CAS Registry Number.

1503-42-0Relevant academic research and scientific papers

STRAD-BINDING AGENTS AND USES THEREOF

-

Paragraph 1253-1255, (2021/08/06)

Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

INHIBITORS OF FATTY ACID BINDING PROTEIN

-

Page/Page column 73, (2012/05/21)

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Novel pyrazine compounds as transforming growth factor (TGF) compounds

-

Page 7; 9, (2010/02/08)

Novel pyrazine compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of trans

An Efficient Synthesis of Arylpyrazines and Bipyridines

Thompson, Wayne J.,Jones, James H.,Lyle, Paulette A.,Thies, J. Eric

, p. 2052 - 2055 (2007/10/02)

The coupling of chloro or bromo pyrazines and pyridines with areneboronic acids in the presence of palladium(0) catalysts is described.By use of the appropriate catalyst, the coupling of pyridineboronic acids was achieved.A convergent synthesis of the pre

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1503-42-0